Profile
Philip Haworth formerly worked at TVAX Biomedical, Inc., as Chief Executive Officer, Intradigm Corp., as Chief Executive Officer, Silence Therapeutics Plc, as Chief Executive Officer & Director from 2010 to 2011, COR Therapeutics, Inc., as Principal, Genencor International, Inc., as Principal, Codexis, Inc., as Vice President-Business Development, and Affymax, Inc., as Principal.
Dr. Haworth received his graduate degree from Stanford University, doctorate degree from The University of Manchester, and undergraduate degree from The University of Southampton.
Former positions of Philip Haworth
| Companies | Position | End |
|---|---|---|
| SILENCE THERAPEUTICS PLC | Chief Executive Officer | 2011-07-31 |
| TVAX BIOM | Chief Executive Officer | - |
| CODEXIS, INC. | Corporate Officer/Principal | - |
| AFFYMAX, INC. | Corporate Officer/Principal | - |
COR Therapeutics, Inc.
 COR Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology COR Therapeutics, Inc.. The principal activities of the Company are the discovery, development and commercialization of novel pharmaceutical products to establish new standards of care for the treatment and prevention of severe cardiovascular diseases. Integrilin was the Company's first product taken from discovery to commercialization. A drug was approved to treat patients who undergo a procedure known as angioplasty to open blood vessels. This drug has also been approved to treat patients with intermittent chest pains known as unstable angina and patients suffering from a kind of Heart attack known as non-Q-wave myocardial infraction | Corporate Officer/Principal | - |
Training of Philip Haworth
| Stanford University | Graduate Degree |
| The University of Manchester | Doctorate Degree |
| The University of Southampton | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 3 |
|---|---|
| AFFYMAX, INC. | Health Technology |
| CODEXIS, INC. | Process Industries |
| SILENCE THERAPEUTICS PLC | Commercial Services |
| Private companies | 4 |
|---|---|
Intradigm Corp.
 Intradigm Corp. Pharmaceuticals: MajorHealth Technology Intradigm Corp. develops drugs and therapies. Its RNAi therapeutic platform comprised of proprietary delivery technologies, potent siRNA sequences and innovative siRNA structural features. The company was founded by Puthupparampil Scaria, Martin C. Woodle, Wei-Wu He and Patrick Y. Lu in 2000 and is headquartered in Palo Alto, CA. | Health Technology |
Genencor International, Inc.
 Genencor International, Inc. BiotechnologyHealth Technology Genencor International, Inc. develops and manufactures enzyme product solutions for industrial, agricultural and health care markets. It finds genes and alters their proteins for use in cleaning, textile, health care, food and animal feed products using gene discovery, molecular evolution, functional genomics and immunology techniques. The company also develops solutions for the biofuels, biodefense and biosafety industries. Genencor International was founded in 1982 and is located in Rochester, NY. | Health Technology |
COR Therapeutics, Inc.
COR Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology COR Therapeutics, Inc.. The principal activities of the Company are the discovery, development and commercialization of novel pharmaceutical products to establish new standards of care for the treatment and prevention of severe cardiovascular diseases. Integrilin was the Company's first product taken from discovery to commercialization. A drug was approved to treat patients who undergo a procedure known as angioplasty to open blood vessels. This drug has also been approved to treat patients with intermittent chest pains known as unstable angina and patients suffering from a kind of Heart attack known as non-Q-wave myocardial infraction | Health Technology |
TVAX Biomedical, Inc.
 TVAX Biomedical, Inc. BiotechnologyHealth Technology TVAX Biomedical, Inc. manufactures and sells healthcare products. It is a biotechnology company, which focuses on the development of targeted cell-based immunotherapies for the treatment of cancer and is performing clinical trials with specific focus on brain cancers. The firm’s proprietary immunologic treatment, TVAX Immunotherapy, uses a patient's cells to create activated, genetically unique cancer-killing T cells that can destroy the patient's cancer cells, including cancer stem cells, which are widely believed to be responsible for cancer growth, spread and metastasis. The company was founded by Gray W. Wood, Frank P. Holladay, Catherine E. Lucasey and Lowell Lynn Tilzer on July 14, 2011 and is headquartered in Lenexa, KS. | Health Technology |
- Stock Market
- Insiders
- Philip Haworth